MND Unit, Neurology Department

Hospital Universitari i Politècnic La Fe

Being the referral center in the Valencian region, the MND Unit of the Hospital Universitari i Politècnic La Fe follows 150 patients per year.

HospitalLaFe_Logo
Hospital Universitari i Politècnic La Fe

The MND Unit of the Hospital Universitari i Politècnic La Fe is the referral centre in the Valencian region and one of the referral centres in Spain for MND patients. We are also part of the European Research Network for rare neuromuscular diseases. Our research group is integrated in the Research Group of Neuromuscular Pathology and Ataxias (GIPNMA) and is part of the Spanish network for research in rare diseases (CIBERER). Our main research interests are the phenotypic and genetic characterization of our patient cohort, the search of biomarkers and clinical trials.

Contact
Location
Hospital Universitari i Politècnic La Fe, Avinguda de Fernando Abril Martorell, Valencia, Spain

Our Specialists

Juan Francisco Vázquez Costa

Principal Investigator

Juan Francisco Vázquez Costa obtained his degree in Medicine from the University […]

Juan Francisco Vázquez Costa
Current trials
Recruiting
Phase ii

CARDINALS

Industry trial
The CARDINALS clinical research study is evaluating a study drug (Utreloxastat) to see if it can help slow ALS symptoms. Researchers will also test the safety and tolerability of the study drug and how the body responds to it. The study drug is a liquid that is swallowed 2 times a day.
Read more
Recruiting
Phase iii

ATLAS trial

Industry trial
Biogen is conducting a clinical trial to evaluate the efficacy and safety and of an investigational drug for adults who do not have any clinical signs or symptoms of Amyotrophic Lateral Sclerosis (ALS) (that definitely indicate the onset of ALS) but do carry a certain superoxide dismutase 1 (SOD1) gene variant.
Read more
Active
Phase iii

PHOENIX trial

Industry trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035' for the treatment of ALS.
Read more
Completed
Phase iii

ADORE trial

Industry trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Read more